| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Positron-Emission Tomography | 33 | 2022 | 290 | 4.030 |
Why?
|
| Fluorodeoxyglucose F18 | 21 | 2022 | 135 | 2.570 |
Why?
|
| Nuclear Medicine | 3 | 2024 | 8 | 2.470 |
Why?
|
| Tomography, X-Ray Computed | 25 | 2017 | 2056 | 2.330 |
Why?
|
| Multimodal Imaging | 17 | 2019 | 111 | 2.250 |
Why?
|
| Radiopharmaceuticals | 16 | 2018 | 155 | 2.230 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 240 | 2.120 |
Why?
|
| Radium | 6 | 2019 | 8 | 1.950 |
Why?
|
| Bone Neoplasms | 10 | 2019 | 431 | 1.740 |
Why?
|
| Positron Emission Tomography Computed Tomography | 7 | 2022 | 78 | 1.420 |
Why?
|
| Osteosarcoma | 3 | 2019 | 258 | 0.980 |
Why?
|
| Radiology | 2 | 2024 | 107 | 0.900 |
Why?
|
| Radioisotopes | 4 | 2019 | 38 | 0.810 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 3547 | 0.790 |
Why?
|
| Fluorine Radioisotopes | 4 | 2018 | 10 | 0.760 |
Why?
|
| Referral and Consultation | 1 | 2024 | 529 | 0.720 |
Why?
|
| Alpha Particles | 1 | 2019 | 1 | 0.650 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 642 | 0.650 |
Why?
|
| Whole Body Imaging | 2 | 2015 | 28 | 0.620 |
Why?
|
| Tumor Burden | 3 | 2016 | 230 | 0.620 |
Why?
|
| Bone Diseases | 1 | 2017 | 45 | 0.550 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 9 | 0.500 |
Why?
|
| Lymphoma | 2 | 2016 | 324 | 0.480 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 141 | 0.460 |
Why?
|
| Radionuclide Imaging | 3 | 2023 | 151 | 0.420 |
Why?
|
| Humans | 50 | 2024 | 123180 | 0.410 |
Why?
|
| Electric Conductivity | 1 | 2011 | 89 | 0.370 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2011 | 12 | 0.370 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2018 | 85 | 0.370 |
Why?
|
| Prognosis | 11 | 2019 | 4512 | 0.360 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 1213 | 0.360 |
Why?
|
| Melanoma | 2 | 2015 | 824 | 0.360 |
Why?
|
| Bias | 2 | 2024 | 125 | 0.340 |
Why?
|
| Lymph Nodes | 4 | 2022 | 376 | 0.320 |
Why?
|
| Middle Aged | 22 | 2022 | 26015 | 0.310 |
Why?
|
| Aged | 21 | 2019 | 19108 | 0.290 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 798 | 0.290 |
Why?
|
| Male | 23 | 2024 | 60173 | 0.290 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 2840 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 334 | 0.260 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 1236 | 0.260 |
Why?
|
| Esophageal Neoplasms | 4 | 2010 | 359 | 0.250 |
Why?
|
| Tomography, Emission-Computed | 2 | 2010 | 43 | 0.250 |
Why?
|
| Breast Neoplasms | 7 | 2012 | 2479 | 0.230 |
Why?
|
| Space Perception | 1 | 2024 | 61 | 0.230 |
Why?
|
| Visual Perception | 1 | 2024 | 124 | 0.220 |
Why?
|
| Diagnostic Imaging | 2 | 2024 | 270 | 0.210 |
Why?
|
| Aged, 80 and over | 11 | 2016 | 6375 | 0.210 |
Why?
|
| Adult | 18 | 2024 | 29032 | 0.210 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2013 | 4 | 0.210 |
Why?
|
| Radiometry | 1 | 2022 | 38 | 0.210 |
Why?
|
| Female | 23 | 2024 | 65562 | 0.210 |
Why?
|
| Young Adult | 8 | 2024 | 8864 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 114 | 0.200 |
Why?
|
| Neoplasm Metastasis | 3 | 2015 | 654 | 0.200 |
Why?
|
| Risk | 1 | 2024 | 743 | 0.200 |
Why?
|
| Adolescent | 7 | 2019 | 19111 | 0.190 |
Why?
|
| Graves Disease | 1 | 2021 | 16 | 0.190 |
Why?
|
| Thyroid Diseases | 1 | 2021 | 33 | 0.190 |
Why?
|
| Hospitals, Pediatric | 2 | 2015 | 781 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2016 | 6029 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2019 | 12142 | 0.170 |
Why?
|
| Research Design | 2 | 2015 | 676 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 1593 | 0.170 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 859 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2022 | 308 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2010 | 70 | 0.160 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 7 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 198 | 0.160 |
Why?
|
| Retrospective Studies | 13 | 2016 | 16062 | 0.160 |
Why?
|
| Reference Values | 3 | 2015 | 697 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 713 | 0.150 |
Why?
|
| Machine Learning | 1 | 2020 | 222 | 0.150 |
Why?
|
| Sodium Fluoride | 1 | 2017 | 11 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1232 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 25 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3670 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 1118 | 0.140 |
Why?
|
| Vaccination | 1 | 2022 | 944 | 0.130 |
Why?
|
| Paraproteinemias | 1 | 2016 | 16 | 0.130 |
Why?
|
| Stroke | 1 | 2024 | 956 | 0.130 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 1305 | 0.130 |
Why?
|
| Tertiary Healthcare | 1 | 2015 | 21 | 0.130 |
Why?
|
| Skeleton | 1 | 2015 | 5 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2016 | 52 | 0.130 |
Why?
|
| Sarcoma, Ewing | 1 | 2016 | 117 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2011 | 577 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2016 | 135 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1439 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2015 | 57 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 105 | 0.120 |
Why?
|
| Neoplasms | 3 | 2016 | 2756 | 0.120 |
Why?
|
| Permeability | 1 | 2015 | 118 | 0.120 |
Why?
|
| Acetabulum | 1 | 2014 | 17 | 0.120 |
Why?
|
| Quality Control | 2 | 2013 | 119 | 0.120 |
Why?
|
| Tissue Distribution | 1 | 2015 | 382 | 0.120 |
Why?
|
| Joint Diseases | 1 | 2014 | 33 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 235 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 93 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2016 | 324 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2015 | 1473 | 0.110 |
Why?
|
| Sirolimus | 2 | 2016 | 220 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 426 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 2 | 2013 | 321 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 1311 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 464 | 0.110 |
Why?
|
| Esophagogastric Junction | 2 | 2010 | 28 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2015 | 262 | 0.110 |
Why?
|
| Breast Diseases | 1 | 2012 | 34 | 0.100 |
Why?
|
| Anus Neoplasms | 1 | 2012 | 38 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2015 | 1243 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 61 | 0.100 |
Why?
|
| Automation | 1 | 2011 | 59 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 400 | 0.090 |
Why?
|
| CA-125 Antigen | 1 | 2010 | 15 | 0.090 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 127 | 0.090 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2010 | 15 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 676 | 0.090 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 2011 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 651 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 756 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 938 | 0.070 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 538 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 524 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1513 | 0.070 |
Why?
|
| Child | 3 | 2016 | 24247 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 408 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 993 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1876 | 0.060 |
Why?
|
| Time Factors | 1 | 2015 | 6221 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 29 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 561 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2014 | 145 | 0.050 |
Why?
|
| Attention | 1 | 2024 | 195 | 0.050 |
Why?
|
| Brain Mapping | 1 | 2024 | 397 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 2113 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 75 | 0.050 |
Why?
|
| Infant | 1 | 2015 | 12371 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2015 | 13904 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 593 | 0.040 |
Why?
|
| Fluorides | 1 | 2018 | 18 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1415 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 1006 | 0.030 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aging | 1 | 2024 | 1176 | 0.030 |
Why?
|
| Copper-transporting ATPases | 1 | 2016 | 25 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 26 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2016 | 78 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 143 | 0.030 |
Why?
|
| Pyrazines | 1 | 2016 | 73 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 91 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 101 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 239 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 130 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2016 | 96 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 369 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 208 | 0.030 |
Why?
|
| Imidazoles | 1 | 2016 | 193 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 570 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 178 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 216 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 861 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 375 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 2967 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 489 | 0.030 |
Why?
|
| Mastitis | 1 | 2012 | 3 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2012 | 4 | 0.020 |
Why?
|
| Residual Volume | 1 | 2012 | 3 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 714 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 622 | 0.020 |
Why?
|
| Axilla | 1 | 2012 | 38 | 0.020 |
Why?
|
| Mastectomy | 1 | 2012 | 64 | 0.020 |
Why?
|
| Granuloma | 1 | 2012 | 68 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 205 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 55 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2012 | 125 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 19 | 0.020 |
Why?
|
| Lactation | 1 | 2012 | 186 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1009 | 0.020 |
Why?
|
| Breast | 1 | 2012 | 214 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 250 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 295 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 75 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 142 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 339 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3291 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 152 | 0.020 |
Why?
|
| Artifacts | 1 | 2010 | 104 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 770 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 353 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 470 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 220 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1236 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 2943 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 361 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 3045 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 502 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1237 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 3327 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 2000 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1599 | 0.010 |
Why?
|
| Inflammation | 1 | 2009 | 1403 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 4703 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 17542 | 0.010 |
Why?
|
| United States | 1 | 2014 | 10660 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 33798 | 0.010 |
Why?
|